Cannon Christopher P, Braunwald E, McCabe Carolyn H, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504. https://doi.org/10.1056/NEJMoa040583.

Article  CAS  PubMed  Google Scholar 

Waters DD, Guyton JR, Herrington DM, et al. Treating to new targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004;93(2):154–8. https://doi.org/10.1016/j.amjcard.2003.09.031.

Article  PubMed  Google Scholar 

Cholesterol Treatment Trialists C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5.

Article  CAS  Google Scholar 

Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319(15):1566–79. https://doi.org/10.1001/jama.2018.2525.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ridker PM, Everett BM, Thuren T. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31. https://doi.org/10.1056/NEJMoa1707914.

Article  CAS  PubMed  Google Scholar 

Nidorf SM, Fiolet ATL, Mosterd A. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838–47. https://doi.org/10.1056/NEJMoa2021372.

Article  CAS  PubMed  Google Scholar 

Vallejo-Vaz AJ, Bray S, Villa G, et al. Implications of ACC/AHA versus ESC/EAS LDL-C recommendations for residual risk reduction in ASCVD: A simulation study from DA VINCI. Cardiovasc Drugs Ther. 2023;37(5):941–59. https://doi.org/10.1007/s10557-022-07343-x.

Article  CAS  PubMed  Google Scholar 

Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357–61. https://doi.org/10.1038/nature08938.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shankman LS, Gomez D, Cherepanova OA, et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med. 2015;21(6):628–37. https://doi.org/10.1038/nm.3866.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation. 2014;129(15):1551–9. https://doi.org/10.1161/CIRCULATIONAHA.113.005015.

Article  CAS  PubMed  Google Scholar 

Henriksbo BD, Tamrakar AK, Phulka JS, Barra NG, Schertzer JD. Statins activate the NLRP3 inflammasome and impair insulin signaling via p38 and mTOR. Am J Physiol Endocrinol Metab. 2020;319(1):E110-6. https://doi.org/10.1152/ajpendo.00125.2020.

Article  CAS  PubMed  Google Scholar 

Koushki K, Shahbaz SK, Mashayekhi K, et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2021;60(2):175–99. https://doi.org/10.1007/s12016-020-08791-9.

Article  CAS  PubMed  Google Scholar 

Sirtori CR, Watts GF, Corsini A, Ruscica M. Understanding the molecular mechanisms of statin pleiotropic effects: the unresolved puzzle. Arch Toxicol. 2023;97(10):2861–87. https://doi.org/10.1007/s00204-023-03492-6.

Article  CAS  Google Scholar 

She J, Tuerhongjiang G, Guo M et al. Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner. Cell Metabolism. 2024;36(2):408 – 21.e5. https://doi.org/10.1016/j.cmet.2023.12.027

Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev. 2011;91(1):327–87. https://doi.org/10.1152/physrev.00047.2009.

Article  PubMed  Google Scholar 

Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282(21):2035–42. https://doi.org/10.1001/jama.282.21.2035.

Article  CAS  PubMed  Google Scholar 

Zhou X, Li C, Xu W. Shear stress activates NLRP3 inflammasome to promote endothelial inflammation. J Cell Physiol. 2020;235(1):491–500. https://doi.org/10.1002/jcp.28919.

Article  CAS  Google Scholar 

Ichihara A, Hayashi M, Koura Y, et al. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens. 2005;19(2):103–9. https://doi.org/10.1038/sj.jhh.1001786.

Article  CAS  PubMed  Google Scholar 

Liao JK, Seto M, Noma K. Rho Kinase (ROCK) Inhibitors. J Cardiovasc Pharmacol. 2007. https://doi.org/10.1097/FJC.0b013e318070d1bd.

Article  PubMed  PubMed Central  Google Scholar 

Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45(1):89–118. https://doi.org/10.1146/annurev.pharmtox.45.120403.095748.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gierig M, Tragoudas A, Haverich A, Wriggers P. Mechano-chemo-biological model of atherosclerosis formation based on the outside-in theory. Biomech Model Mechanobiol. 2024;23(2):539–52. https://doi.org/10.1007/s10237-023-01790-7.

Article  PubMed  Google Scholar 

Chen S, Zhang H, Hou Q, Zhang Y, Qiao A. Multiscale modeling of vascular remodeling induced by wall shear stress. Front Physiol. 2021;12:808999. https://doi.org/10.3389/fphys.2021.808999.

Article  PubMed  Google Scholar 

Talic S, Marquina C, Ofori-Asenso R, et al. Switching, persistence and adherence to statin therapy: a retrospective cohort study using the Australian National pharmacy data. Cardiovasc Drugs Ther. 2022;36(5):867–77. https://doi.org/10.1007/s10557-021-07199-7.

Article  CAS  PubMed  Google Scholar 

Sehayek D, Cole J, Björnson E, et al. ApoB, LDL-C and non-HDL-C as markers of cardiovascular risk. J Clin Lipidol. 2025. https://doi.org/10.1016/j.jacl.2025.05.024.

Article  PubMed  Google Scholar 

Mortensen MB. ApoB triumphs once more over LDL-C and non-HDL-C in risk prediction: ready for guidelines? Eur Heart J. 2024;45(27):2419–21. https://doi.org/10.1093/eurheartj/ehae257.

Article  CAS  PubMed  Google Scholar 

Abohelwa M, Kopel J, Shurmur S, et al. The Framingham study on cardiovascular disease risk and stress-defenses: a historical review. J Vasc Dis. 2023;2(1):122–64.

Google Scholar 

Sabeel S, Motaung B, Nguyen KA, et al. Impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases: a systematic review and meta-analysis. PLoS One. 2025;20(5):e0323749. https://doi.org/10.1371/journal.pone.0323749.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ridker Paul M, Danielson E, Fonseca Francisco AH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. https://doi.org/10.1056/NEJMoa0807646.

Article  CAS  PubMed  Google Scholar 

Sattar N, Preiss D, Murray HM. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42. https://doi.org/10.1016/S0140-6736(09)61965-6.

Article  CAS  PubMed  Google Scholar 

Mylonas E, Mamareli C, Filippakis M, et al. A mathematical model of statin anti-hyperlipidemic drug reactivity and diverse concentrations of risk toxicity. J Clin Med. 2025;14(7):2331.

Article